BIBLIOGRAPHIC RECORD

Rapamycin, an Immunosuppressant and mTORC1 Inhibitor, Triples the antidepressant Response Rate of Ketamine at 2 Weeks Following Treatment: A double-blind, placebo-controlled, cross-over, randomized clinical trial

This record contains bibliographic metadata. Open the linked source to check the work; the record does not include its full text.

Recorded authors
Chadi G. Abdallah; Lynnette A. Averill; Ralitza Gueorguieva; Selin Goktas; Prerana Purohit; Mohini Ranganathan; Deepak Cyril D’Souza; Richard N. Formica; Steven M. Southwick; Ronald S. Duman; Gerard Sanacora; John H. Krystal
Source of metadata
OpenAlex
Year recorded
2018

Public identifiers and source

Open the source record

Reference

Chadi G. Abdallah; Lynnette A. Averill; Ralitza Gueorguieva; Selin Goktas; Prerana Purohit; Mohini Ranganathan; Deepak Cyril D’Souza; Richard N. Formica; Steven M. Southwick; Ronald S. Duman; Gerard Sanacora; John H. Krystal. (2018). Rapamycin, an Immunosuppressant and mTORC1 Inhibitor, Triples the antidepressant Response Rate of Ketamine at 2 Weeks Following Treatment: A double-blind, placebo-controlled, cross-over, randomized clinical trial. https://openalex.org/W2904961275

Reference assembled from the available metadata. Check and cite the original publication before reusing a claim.

Permanent record URL: https://brain.psiconautica.org/en/documentos/d-df3171036d5a3f49a5eaa2e3b576ed11/